- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00035061
A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium
July 18, 2006 updated by: Eli Lilly and Company
Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States
-
Palo Alto, California, United States
-
-
Florida
-
Boca Raton, Florida, United States
-
Tampa, Florida, United States
-
-
Illinois
-
Decatur, Illinois, United States
-
-
Indiana
-
Indianapolis, Indiana, United States
-
Lafayette, Indiana, United States
-
Muncie, Indiana, United States
-
South Bend, Indiana, United States
-
-
Kansas
-
Lenexa, Kansas, United States
-
-
Kentucky
-
Saint Mathews, Kentucky, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
Nebraska
-
Omaha, Nebraska, United States
-
-
Ohio
-
Cleveland, Ohio, United States
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
-
Pittsburgh, Pennsylvania, United States
-
-
Tennessee
-
Nashville, Tennessee, United States
-
-
Texas
-
Fort Worth, Texas, United States
-
Houston, Texas, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- You must have been diagnosed with bladder cancer that has recurred or moved to a new part of the body.
- You must have at least one tumor that can be physically measured or scanned by x-ray.
- You may not have had previous chemotherapy (drug) treatment OR you have had surgery followed by one chemotherapy treatment at least 4 months ago.
Exclusion Criteria:
- You may not have used an experimental medicine or device within the past month.
- Cancer that has spread to your brain.
- If you are unwilling or unable to take folic acid or vitamin B12 supplements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
May 2, 2002
First Submitted That Met QC Criteria
May 2, 2002
First Posted (Estimate)
May 3, 2002
Study Record Updates
Last Update Posted (Estimate)
July 19, 2006
Last Update Submitted That Met QC Criteria
July 18, 2006
Last Verified
July 1, 2006
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Neoplastic Processes
- Neoplasms
- Neoplasm Metastasis
- Urologic Neoplasms
- Carcinoma, Transitional Cell
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Folic Acid Antagonists
- Pemetrexed
Other Study ID Numbers
- 4698
- H3E-MC-JMEU
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urologic Neoplasms
-
University Hospital, GhentCompletedSurgery | Bladder Cancer | Urologic CancerBelgium
-
The Catholic University of KoreaActive, not recruitingUrologic CancerKorea, Republic of
-
Exosome Diagnostics, Inc.CompletedUrologic CancerUnited States, Germany
-
Fox Chase Cancer CenterBristol-Myers SquibbCompletedUrologic NeoplasmUnited States
-
Ricardo RendonTerminatedKidney NeoplasmsCanada
-
M.D. Anderson Cancer CenterUnknown
-
Urological Research Network, LLCRecruitingKidney NeoplasmsUnited States
-
Lindis Biotech GmbHRecruitingUrinary Bladder NeoplasmsGermany
-
Association of Urologic Oncology (AUO)IAG-N at German Cancer Association (Deutsche Krebsgesellschaft e. V.)Not yet recruiting
Clinical Trials on pemetrexed
-
Boehringer IngelheimTerminatedCarcinoma, Non-Small-Cell LungJapan
-
Shanghai Shengdi Pharmaceutical Co., LtdNot yet recruitingNon-squamous Non-small Cell Lung CancerChina
-
Northwestern UniversityNational Cancer Institute (NCI)UnknownLymphoma | Brain and Central Nervous System Tumors | Metastatic CancerUnited States
-
Rongjie TaoNational Natural Science Foundation of ChinaUnknown
-
Ain Shams UniversityUnknown
-
GlaxoSmithKlineCompletedLung Cancer, Non-Small CellDenmark, United Kingdom
-
PfizerTerminatedCarcinoma, Non-Small Cell LungUnited States, Germany, Italy
-
Eli Lilly and CompanyCompletedNon-Small Cell Lung Cancer Metastatic | Nonsquamous Non-Small Cell Neoplasm of Lung | Non-Small Cell Lung Cancer Stage IIIBUnited Kingdom, Sweden
-
Norwegian University of Science and TechnologySt. Olavs HospitalTerminatedCarcinoma, Non-small-cell LungNorway
-
Spanish Lung Cancer GroupTerminatedCarcinoma, Non Small Cell LungSpain